Funds › Sio Capital Management, LLC
Sio Capital Management, LLC
13F for Q2 2026, filed Aug 14, 2026. 57 positions worth $604.3M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$604.3M
−$93.0M (13.3%) vs Q1 2026
Positions
57
73 in Q1 2026
Top 10 share
48.4%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Sio Capital Management, LLC in the latest 13F quarter?
Using 13F.ai, how has Sio Capital Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Sio Capital Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | AVR Anteris Technologies Global Corp. | 5.55M | $54.6M | 9.0% | +3.0% | 13F ↗ |
| 2 | COR Cencora, Inc. | 173,588 | $49.1M | 8.1% | +72.0% | 13F ↗ |
| 3 | MMS Maximus, Inc. | 715,267 | $38.5M | 6.4% | -7.0% | 13F ↗ |
| 4 | ALLO Allogene Therapeutics, Inc. | 13.32M | $27.7M | 4.6% | New | 13F ↗ |
| 5 | GMED Globus Medical, Inc. | 301,816 | $23.8M | 3.9% | New | 13F ↗ |
| 6 | GSK GSK plc · ADR | 436,700 | $22.9M | 3.8% | +13.2% | 13F ↗ |
| 7 | TYRA Tyra Biosciences, Inc. | 695,315 | $22.2M | 3.7% | +14.8% | 13F ↗ |
| 8 | WAY Waystar Holding Corp. | 925,834 | $19.0M | 3.1% | -43.6% | 13F ↗ |
| 9 | IDYA IDEAYA Biosciences, Inc. | 480,383 | $17.9M | 3.0% | New | 13F ↗ |
| 10 | ORKA Oruka Therapeutics, Inc. | 177,118 | $16.9M | 2.8% | +33.7% | 13F ↗ |
| 11 | CI The Cigna Group | 57,750 | $15.9M | 2.6% | New | 13F ↗ |
| 12 | SNY Sanofi | 364,200 | $15.5M | 2.6% | +52.0% | 13F ↗ |
| 13 | ICLR ICON plc | 88,186 | $15.3M | 2.5% | -71.2% | 13F ↗ |
| 14 | VTRS Viatris Inc. | 954,299 | $15.2M | 2.5% | New | 13F ↗ |
| 15 | Cross Ctry Healthcare Inc | 1.10M | $14.5M | 2.4% | Unchanged | 13F ↗ |
| 16 | RAPP Rapport Therapeutics, Inc. | 307,657 | $12.8M | 2.1% | -16.1% | 13F ↗ |
| 17 | ABT Abbott Laboratories | 128,656 | $11.7M | 1.9% | -31.0% | 13F ↗ |
| 18 | CELC Celcuity Inc. | 110,022 | $11.5M | 1.9% | -43.2% | 13F ↗ |
| 19 | ZBH Zimmer Biomet Holdings, Inc. | 131,445 | $11.3M | 1.9% | +110% | 13F ↗ |
| 20 | REGN Regeneron Pharmaceuticals, Inc. | 18,000 | $11.2M | 1.9% | New | 13F ↗ |
| 21 | BMY Bristol-Myers Squibb Company | 193,500 | $11.1M | 1.8% | New | 13F ↗ |
| 22 | MDT Medtronic plc. | 142,500 | $11.1M | 1.8% | New | 13F ↗ |
| 23 | VIR Vir Biotechnology, Inc. | 1.08M | $11.0M | 1.8% | -28.2% | 13F ↗ |
| 24 | SENS Senseonics Holdings, Inc. | 1.59M | $9.0M | 1.5% | +1276% | 13F ↗ |
| 25 | EYPT EyePoint, Inc. | 623,130 | $8.9M | 1.5% | -13.7% | 13F ↗ |
| 26 | Cybin Inc | 1.30M | $8.6M | 1.4% | New | 13F ↗ |
| 27 | ANIP ANI Pharmaceuticals, Inc. | 97,305 | $8.1M | 1.3% | -63.4% | 13F ↗ |
| 28 | TARA Protara Therapeutics, Inc. | 1.92M | $7.3M | 1.2% | -2.4% | 13F ↗ |
| 29 | RLMD Relmada Therapeutics, Inc. | 1.00M | $6.9M | 1.1% | +4.0% | 13F ↗ |
| 30 | TNGX Tango Therapeutics, Inc. | 208,500 | $6.5M | 1.1% | New | 13F ↗ |
| 31 | AQST Aquestive Therapeutics, Inc. | 1.49M | $6.2M | 1.0% | -22.7% | 13F ↗ |
| 32 | DNTH Dianthus Therapeutics, Inc. | 59,254 | $5.8M | 1.0% | -84.0% | 13F ↗ |
| 33 | SION Sionna Therapeutics, Inc. | 127,808 | $5.6M | 0.9% | -56.6% | 13F ↗ |
| 34 | OCUL Ocular Therapeutix, Inc. | 539,493 | $5.3M | 0.9% | -44.3% | 13F ↗ |
| 35 | ZBIO Zenas BioPharma, Inc. | 208,557 | $5.3M | 0.9% | -37.1% | 13F ↗ |
| 36 | DRUG Bright Minds Biosciences Inc. | 73,952 | $5.2M | 0.9% | -14.1% | 13F ↗ |
| 37 | OKUR OnKure Therapeutics, Inc. | 1.08M | $4.9M | 0.8% | Unchanged | 13F ↗ |
| 38 | SVRA Savara, Inc. | 617,675 | $3.8M | 0.6% | +0.6% | 13F ↗ |
| 39 | PMVP PMV Pharmaceuticals, Inc. | 2.63M | $3.5M | 0.6% | -14.4% | 13F ↗ |
| 40 | AVAH Aveanna Healthcare Holdings Inc. | 369,036 | $3.2M | 0.5% | New | 13F ↗ |
| 41 | OVID Ovid Therapeutics Inc. | 1.01M | $2.7M | 0.4% | -19.7% | 13F ↗ |
| 42 | IMNM Immunome, Inc. | 124,168 | $2.6M | 0.4% | -24.8% | 13F ↗ |
| 43 | ANTX AN2 Therapeutics, Inc. | 529,933 | $2.6M | 0.4% | -19.4% | 13F ↗ |
| 44 | SER Serina Therapeutics, Inc. | 1.00M | $1.9M | 0.3% | Unchanged | 13F ↗ |
| 45 | ALGS Aligos Therapeutics, Inc. | 327,237 | $1.9M | 0.3% | Unchanged | 13F ↗ |
| 46 | IBIO iBio, Inc. | 904,268 | $1.6M | 0.3% | Unchanged | 13F ↗ |
| 47 | XLO Xilio Therapeutics, Inc. | 152,464 | $1.5M | 0.2% | Unchanged | 13F ↗ |
| 48 | AORT Artivion, Inc. | 48,481 | $1.1M | 0.2% | New | 13F ↗ |
| 49 | BBOT BridgeBio Oncology Therapeutics, Inc. | 130,628 | $995.4K | 0.2% | Unchanged | 13F ↗ |
| 50 | TELA TELA Bio, Inc. | 636,300 | $477.2K | 0.1% | Unchanged | 13F ↗ |
Showing the top 50 of 57 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
15 new, 10 added to, 21 trimmed, 31 exited, 11 unchanged. By estimated dollars.
New positions (15)
| ALLO Allogene Therapeutics, Inc. | 13.32M | New | $27.7M |
| GMED Globus Medical, Inc. | 301,816 | New | $23.8M |
| IDYA IDEAYA Biosciences, Inc. | 480,383 | New | $17.9M |
| CI The Cigna Group | 57,750 | New | $15.9M |
| VTRS Viatris Inc. | 954,299 | New | $15.2M |
| REGN Regeneron Pharmaceuticals, Inc. | 18,000 | New | $11.2M |
| BMY Bristol-Myers Squibb Company | 193,500 | New | $11.1M |
| MDT Medtronic plc. | 142,500 | New | $11.1M |
| Cybin Inc | 1.30M | New | $8.6M |
| TNGX Tango Therapeutics, Inc. | 208,500 | New | $6.5M |
Added to (10)
| COR Cencora, Inc. | 173,588 | +72.0% | $20.6M |
| SENS Senseonics Holdings, Inc. | 1.59M | +1276% | $8.4M |
| ZBH Zimmer Biomet Holdings, Inc. | 131,445 | +110% | $5.9M |
| SNY Sanofi | 364,200 | +52.0% | $5.3M |
| ORKA Oruka Therapeutics, Inc. | 177,118 | +33.7% | $4.2M |
| TYRA Tyra Biosciences, Inc. | 695,315 | +14.8% | $2.9M |
| GSK GSK plc · ADR | 436,700 | +13.2% | $2.7M |
| AVR Anteris Technologies Global Corp. | 5.55M | +3.0% | $1.6M |
| RLMD Relmada Therapeutics, Inc. | 1.00M | +4.0% | $266.8K |
| SVRA Savara, Inc. | 617,675 | +0.6% | $23.3K |
Trimmed (21)
| ICLR ICON plc | 88,186 | -71.2% | -$37.9M |
| DNTH Dianthus Therapeutics, Inc. | 59,254 | -84.0% | -$30.3M |
| WAY Waystar Holding Corp. | 925,834 | -43.6% | -$14.7M |
| ANIP ANI Pharmaceuticals, Inc. | 97,305 | -63.4% | -$13.9M |
| CELC Celcuity Inc. | 110,022 | -43.2% | -$8.8M |
| SION Sionna Therapeutics, Inc. | 127,808 | -56.6% | -$7.3M |
| ABT Abbott Laboratories | 128,656 | -31.0% | -$5.3M |
| VIR Vir Biotechnology, Inc. | 1.08M | -28.2% | -$4.3M |
| OCUL Ocular Therapeutix, Inc. | 539,493 | -44.3% | -$4.2M |
| ZBIO Zenas BioPharma, Inc. | 208,557 | -37.1% | -$3.1M |
Exited (31)
| CORT Corcept Therapeutics Incorporated | 674,759 | Exited | -$27.2M |
| LIVN LivaNova PLC | 421,615 | Exited | -$26.8M |
| EMBC Embecta Corp. | 1.85M | Exited | -$16.3M |
| ABVX Abivax SA · ADR | 135,800 | Exited | -$15.1M |
| HAE Haemonetics Corporation | 220,672 | Exited | -$12.4M |
| TFX Teleflex Incorporated | 94,800 | Exited | -$11.3M |
| BMRN BioMarin Pharmaceutical Inc. | 194,226 | Exited | -$11.0M |
| GPCR Structure Therapeutics Inc. | 209,093 | Exited | -$10.1M |
| BHVN Biohaven Ltd. | 1.16M | Exited | -$9.8M |
| MNPR Monopar Therapeutics Inc. | 173,506 | Exited | -$9.5M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer